Breaking News, Financial News

Amgen 1Q Results

Horizon Therapeutics acquisition adds $914 million of sales in the quarter.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Amgen 1Q Revenues: $7.4 billion (+22%) 1Q Loss: $113 million (earnings were $2.8 billion 1Q23) Comments: Repatha (evolocumab) sales increased 33% to $517 million in the quarter, driven by 44% volume growth. TEZSPIRE (tezepelumab-ekko) generated $173 million of sales in the quarter, up 80%, primarily driven by volume growth. Otezla (apremilast) sales were $394 million, an increase of 1%.  Enbrel (etanercept) generated $567 million of sales, down 2%. AMJEVITA/AMGEVITA (adalimumab) generated $16...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters